Saint-Louis University Hospital, Paris, France.
IPC, Lyon, France.
JAMA. 2015 Oct 27;314(16):1711-9. doi: 10.1001/jama.2015.12402.
Noninvasive ventilation has been recommended to decrease mortality among immunocompromised patients with hypoxemic acute respiratory failure. However, its effectiveness for this indication remains unclear.
To determine whether early noninvasive ventilation improved survival in immunocompromised patients with nonhypercapnic acute hypoxemic respiratory failure.
DESIGN, SETTING, AND PARTICIPANTS: Multicenter randomized trial conducted among 374 critically ill immunocompromised patients, of whom 317 (84.7%) were receiving treatment for hematologic malignancies or solid tumors, at 28 intensive care units (ICUs) in France and Belgium between August 12, 2013, and January 2, 2015.
Patients were randomly assigned to early noninvasive ventilation (n = 191) or oxygen therapy alone (n = 183).
The primary outcome was day-28 mortality. Secondary outcomes were intubation, Sequential Organ Failure Assessment score on day 3, ICU-acquired infections, duration of mechanical ventilation, and ICU length of stay.
At randomization, median oxygen flow was 9 L/min (interquartile range, 5-15) in the noninvasive ventilation group and 9 L/min (interquartile range, 6-15) in the oxygen group. All patients in the noninvasive ventilation group received the first noninvasive ventilation session immediately after randomization. On day 28 after randomization, 46 deaths (24.1%) had occurred in the noninvasive ventilation group vs 50 (27.3%) in the oxygen group (absolute difference, -3.2 [95% CI, -12.1 to 5.6]; P = .47). Oxygenation failure occurred in 155 patients overall (41.4%), 73 (38.2%) in the noninvasive ventilation group and 82 (44.8%) in the oxygen group (absolute difference, -6.6 [95% CI, -16.6 to 3.4]; P = .20). There were no significant differences in ICU-acquired infections, duration of mechanical ventilation, or lengths of ICU or hospital stays.
Among immunocompromised patients admitted to the ICU with hypoxemic acute respiratory failure, early noninvasive ventilation compared with oxygen therapy alone did not reduce 28-day mortality. However, study power was limited.
clinicaltrials.gov Identifier: NCT01915719.
无创通气已被推荐用于降低免疫功能低下的低氧性急性呼吸衰竭患者的死亡率。然而,其对该适应症的疗效仍不清楚。
确定早期无创通气是否能改善免疫功能低下的非高碳酸血症性急性低氧性呼吸衰竭患者的生存率。
设计、地点和参与者:这是一项多中心随机试验,在法国和比利时的 28 个重症监护病房(ICUs)中,共纳入了 374 名患有免疫功能低下的重症患者,其中 317 名(84.7%)正在接受血液恶性肿瘤或实体瘤的治疗,于 2013 年 8 月 12 日至 2015 年 1 月 2 日进行。
患者被随机分配至早期无创通气(n=191)或单独氧疗(n=183)组。
主要结局是 28 天死亡率。次要结局是第 3 天序贯器官衰竭评估评分、ICU 获得性感染、机械通气时间和 ICU 住院时间。
在随机分组时,无创通气组的中位氧流量为 9 L/min(四分位距,5-15),氧疗组为 9 L/min(四分位距,6-15)。无创通气组的所有患者在随机分组后立即接受第一次无创通气治疗。在随机分组后的第 28 天,无创通气组有 46 例(24.1%)死亡,而氧疗组有 50 例(27.3%)(绝对差异,-3.2 [95%CI,-12.1 至 5.6];P=0.47)。共有 155 例患者发生了氧合失败(41.4%),其中无创通气组 73 例(38.2%),氧疗组 82 例(44.8%)(绝对差异,-6.6 [95%CI,-16.6 至 3.4];P=0.20)。两组 ICU 获得性感染、机械通气时间或 ICU 和住院时间均无显著差异。
在因低氧性急性呼吸衰竭而入住 ICU 的免疫功能低下患者中,与单独氧疗相比,早期无创通气并未降低 28 天死亡率。然而,研究的效能有限。
clinicaltrials.gov 标识符:NCT01915719。